HNF4A and hepatocellular carcinoma: To date, HNF4α-negative and FOXM1-positive HCC with activated Wnt/β-catenin signaling, namely the aggressive phenotype, should be a candidate for systemic chemotherapy, including ICIs, but has not yet been effectively diagnosed using current imaging techniques.